acturing site in Groningen, the Netherlands
, DSM is starting up operations in 2013 in Brisbane, Australia
, with the support of the Government of Queensland
and the Commonwealth of Australia
. The Brisbane
facility is DSM's prototype 'biologics plant of the future'
for the production of biopharmaceuticals employing DSM's proprietary technologies. DSM's technologies drive down cost, processing times, scale-up risk and capital requirements to meet market demand for developing cost-effective, lifesaving medications.
"Partnering with DSM for its antibody process development and manufacturing enables DecImmune to move rapidly through late preclinical studies and into clinical development. DSM's experience, capacity, and technical expertise in Groningen and Brisbane meet the full range of DecImmune's manufacturing needs. We look forward to working with one of the world's leading science-based companies as our manufacturing partner," stated Christopher K. Mirabelli , Ph.D., President and CEO of DecImmune and Managing Director at HealthCare Ventures, DecImmune's lead investor.
"In line with DSM's stated strategy, and fulfillment of its commitment to bring manufacturing and technological excellence to the global biopharmaceutical market, this agreement with DecImmune represents the best of what DSM is doing to help our customers serve critical needs in healthcare. The combination of the Groningen and Brisbane operations will support DecImmune throughout the development process and on to clinical trials." declared Alexander Wessels , President and CEO of DSM Pharmaceutical Products.
David Hughes , CEO of BioPharmaceuticals Australia (BPA), said "We have always been o
Page: 1 2 3 4 Related medicine technology :1
|SOURCE DSM Pharmaceutical Products|
Copyright©2012 PR Newswire.
All rights reserved
. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank2
. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry3
. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium4
. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress5
. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure6
. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research7
. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain8
. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA9
. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics10
. Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent11
. Halozyme Therapeutics Names Matt Posard to Board of Directors